(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 5.43% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Haemonetics's revenue in 2026 is $1,334,027,000.On average, 12 Wall Street analysts forecast HAE's revenue for 2027 to be $64,215,173,979, with the lowest HAE revenue forecast at $61,670,198,931, and the highest HAE revenue forecast at $67,169,162,874. On average, 11 Wall Street analysts forecast HAE's revenue for 2028 to be $67,623,622,704, with the lowest HAE revenue forecast at $64,260,619,962, and the highest HAE revenue forecast at $71,531,977,242.
In 2029, HAE is forecast to generate $71,077,517,412 in revenue, with the lowest revenue forecast at $68,078,082,534 and the highest revenue forecast at $74,804,088,018.